Feature | December 24, 2013

American College of Cardiology Previews Top Cardiology Stories of 2014

acc pharmaceuticals renal denervation heart valve repair antiplatelet therapy
December 24, 2013 — Clinical trials for a promising new class of cholesterol-lowering medications, a long-awaited repair of the Medicare formula for paying physicians, the Affordable Care Act, new technology and the implementation of new prevention guidelines are among the top developments in cardiology anticipated for 2014.
 
Leaders from the American College of Cardiology (ACC) identified the following issues to watch for in the new year:
 
Affordable Care Act’s Individual Mandate for Health Insurance Coverage
The new health plan takes effect Jan. 1. The medical community, including cardiology, will be watching and working to adjust as payment models change and more patients have access to medical care. Some heart disease patients may see a cardiologist for the first time as they get access to care through plans established because of the Affordable Care Act.
 
Sustainable Growth Rate Permanent Fix
Congress seems closer than ever to passing a fix to the flawed formula for calculating physician pay under Medicare enacted almost two decades ago. The Senate Finance and House Ways and Means committees passed a permanent sustainable growth rate (SGR) fix Dec. 12, but the House and Senate only passed a three-month patch to avoid a 20 percent Medicare payment cut on Jan. 1. The full Congress is expected to vote on and pass legislation to permanently repeal the SGR in 2014, before that patch expires. A permanent repeal would be good news for Medicare patients, as many physicians would be unable to continue to see Medicare patients if payments for physicians were cut so dramatically. It would also stop the almost annual exercise of Congress approving a last-minute patch.
 
Development of PCSK9 Inhibitors
Multiple trials are in progress for this anticipated new class of drugs that dramatically decrease LDL cholesterol, known as “bad” cholesterol. PSCK9 inhibitors mimic a gene found in people with naturally low LDL. The drug interferes with the destruction of the LDL receptor. The new class could have a big impact on the treatment of patients not able to tolerate statin medications or those with very high LDL who have not responded to other treatments.
 
Implementation of New American College of Cardiology/American Heart Association Prevention Guidelines
Guidelines for obesity, lifestyle management to reduce cardiovascular risk, cholesterol management and risk assessment were released in November based on systematic reviews of evidence initiated by the National Heart, Lung and Blood Institute (NHLBI). The guidelines will continue to be discussed and debated, and education programs will be developed to help physicians incorporate them into daily practice. The ACC and AHA, with support from NHLBI, will also start work on a guideline for the management of hypertension.
 
Rollout of Mitral Valve Clip
In October 2013, the U.S. Food and Drug Administration (FDA) approved a transcatheter procedure for treatment of prohibitive risk patients with severe degenerative mitral regurgitation, a heart disorder in which the mitral valve does not close properly when the heart pumps blood. This procedure offers a chance for treatment for these patients. An experienced heart team composed of an interventional cardiologist, cardiac surgeon and others will dictate use of this procedure. The ACC and the Society of Thoracic Surgeons (STS) will also add a mitral module to the National Cardiovascular Data Registry TVT Registry and begin reporting data in 2014.
 
Expanded Use of Novel Oral Anticoagulants in Patients With Atrial Fibrillation or Venous Thromboembolic Disease
These new medications began to get traction in the market in 2013 but still lagged behind warfarin, which was the only anticoagulant on the market for decades. Recent trial results have shown these new medications, which cost more per dose, improve outcomes compared to warfarin and do not require extensive monitoring or dietary/medication restrictions.
 
Results of Dual Antiplatelet Therapy Study (DAPT)
Results of this phase IV study are expected to be released in 2014 and may impact the duration of such treatment following coronary stenting across a wide spectrum of patients. Researchers are evaluating 12 months versus 30 months as the optimal duration of therapy in these patients.
 
Potential New Therapy for Refractory Hypertension
The results of a phase III trial of renal denervation for hypertension are expected in early 2014 and could eventually lead to FDA approval for a renal denervation device. With this procedure, a catheter is inserted into the renal artery to deliver radiofrequency pulses to reduce nerve signaling and lower blood pressure. If successful, it may be an alternative treatment for patients with refractory hypertension — those patients whose blood pressure remains elevated after treatment with three medications including a diuretic.
 
Continued Growth of Cardio-Oncology
This cardiology subspecialty is focused on the cardiovascular manifestations of cancer and complications of its treatment. It is offered at select hospitals across the country to help cancer patients maintain their heart health during and after treatment. Look for it to expand rapidly to more hospitals across the country.
 
For more information: www.cardiosource.org

Related Content

News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
4Tech, TriCinch TTVR, transcather tricuspid valve repair device, first implant
News | Heart Valve Technology| September 22, 2016
4Tech Inc. announced that its TriCinch device has been used in the world’s first-ever successful transcatheter...
Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, CX50

Transesophageal echo (TEE) has become an essential part of the new transcatheter structrual heart therapies, giving rise to a new sub-speciality of interventional echocardiography.  

Feature | Cath Lab Navigation Aids| September 21, 2016 | Dave Fornell
The rapid growth of transcatheter structural heart procedures and the need for increased use of echocardiography as a
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Edwards sapien, intermediate risk patients, CE mark
News | Heart Valve Technology| September 20, 2016
September 19, 2016 — Edwards Lifesciences received European CE mark to expand use of the Edwards Sapien 3 transcathet
Valtech Cardio, Cardioband Tricuspid, Cardioband Mitral, PCR London Valves 2016, study data
News | Heart Valve Technology| September 19, 2016
Valtech Cardio Ltd. announced that it will present the first-in-man data for its Cardioband Tricuspid (TR) system at...
Lotus Edge Valve, CE mark, boston scientific, TAVR, TAVI

The Lotus Edge system in its deployed position. The Lotus valve expands outward as it is compressed and buckled in the deployment position. It also has a skirt to help eliminate paravalvular leaks.

News | Heart Valve Technology| September 19, 2016
September 19, 2016 — Boston Scientific received European CE mark approval for its Lotus Edge Valve System, the compan
Xeltis bioabsorbable aortic conduit, endogenous tissue restoration, ETR, preclinical data, ISACB 2016
News | Heart Valve Technology| September 09, 2016
Six-month preclinical data from trials of a Xeltis bioabsorbable aortic conduit were presented at the 2016 scientific...
Pradaxa, dabigatran, GLORIA-AF registry, ESC Congress 2016, NVAF
News | Antiplatelet and Anticoagulation Therapies| September 01, 2016
First outcome results from the GLORIA-AF Registry show that treatment with Pradaxa (dabigatran etexilate mesylate) was...
Edwards Intuity aortic valve, surgical aortic valve replacement, PinnacleHealth, first U.S. implants
News | Heart Valve Technology| August 26, 2016
This week, PinnacleHealth, Harrisburg, Pa., became the first hospital in the country to implant the Edwards Intuity...
Overlay Init